

Predictive Performance of the Modification of Diet in Renal Disease and Cockcroft-Gault Equations for Estimating Renal Function

Marc Froissart,^{*†§} Jerome Rossert,^{†||} Christian Jacquot,^{‡§} Michel Paillard,^{*†§} and Pascal Houillier^{*†§}

^{*}Department of Physiology and Biophysics, Georges Pompidou Hospital (AP-HP); [†]INSERM U652 and IFR 58;

[‡]Department of Nephrology, Georges Pompidou Hospital (AP-HP); [§]René Descartes Medical School, Paris V University; and ^{||}Paris VI University, Paris, France

Recent recommendations emphasize the need to assess kidney function using creatinine-based predictive equations to optimize the care of patients with chronic kidney disease. The most widely used equations are the Cockcroft-Gault (CG) and the simplified Modification of Diet in Renal Disease (MDRD) formulas. However, they still need to be validated in large samples of subjects, including large non-U.S. cohorts. Renal clearance of ⁵¹Cr-EDTA was compared with GFR estimated using either the CG equation or the MDRD formula in a cohort of 2095 adult Europeans (863 female and 1232 male; median age, 53.2 yr; median measured GFR, 59.8 ml/min per 1.73 m²). When the entire study population was considered, the CG and MDRD equations showed very limited bias. They overestimated measured GFR by 1.94 ml/min per 1.73 m² and underestimated it by 0.99 ml/min per 1.73 m², respectively. However, analysis of subgroups defined by age, gender, body mass index, and GFR level showed that the biases of the two formulas could be much larger in selected populations. Furthermore, analysis of the SD of the mean difference between estimated and measured GFR showed that both formulas lacked precision; the CG formula was less precise than the MDRD one in most cases. In the whole study population, the SD was 15.1 and 13.5 ml/min per 1.73 m² for the CG and MDRD formulas, respectively. Finally, 29.2 and 32.4% of subjects were misclassified when the CG and MDRD formulas were used to categorize subjects according to the Kidney Disease Outcomes Quality Initiative chronic kidney disease classification, respectively.

J Am Soc Nephrol 16: 763–773, 2005. doi: 10.1681/ASN.2004070549

The prevalent and incident rates of ESRD are continuously increasing in all Western countries. Data from the U.S. Renal Data System predict that the number of patients who were registered with ESRD in 1997 will have doubled in 2010, leading to approximately 700,000 patients with ESRD and 2.2 million patients in 2030 (1), and similar trends are anticipated in other countries (2–4). To level off these incident rates, various initiatives, such as the Kidney Disease Outcomes Quality Initiative (K/DOQI), have provided physicians with guidelines to optimize the care of patients with chronic kidney disease (CKD). These guidelines emphasize the need to assess kidney function using predictive equations rather than serum creatinine alone (5). However, they also highlight that these equations still need to be validated in large samples of subjects, in particular that they should be tested in non-U.S. populations and in individuals with mild decrease in kidney function or normal GFR (5). Validation of the predictive formulas is also particularly important for patients aged 65 and older, who by far have the highest incident rates of ESRD (1,6,7).

The formulas that are most widely used to estimate kidney function and that are recommended in adults by the K/DOQI guidelines (5) are the Cockcroft-Gault (CG) formula (8) and the recently developed (9) and later simplified (10) Modification of Diet in Renal Disease (MDRD) formula. The CG formula is an estimate of creatinine clearance originally developed in a population of 236 Canadian patients, 209 of which were male. The MDRD formulas have been developed as an estimation of ¹²⁵I-iothalamate renal clearance–based GFR measurement in a population of 1628 patients with previously diagnosed CKD (9–11). The mean GFR in this population was 39.8 ± 21.2 ml/min per 1.73 m², and the mean age of the cohort was 50.6 ± 12.7 yr.

The K/DOQI CKD guidelines have established a five-stage classification of patients with CKD that is based solely on kidney function. These stages are defined by GFR ≥90 ml/min per 1.73 m² (stage 1), 60 to 89 ml/min per 1.73 m² (stage 2), 30 to 59 ml/min per 1.73 m² (stage 3), 15 to 29 ml/min per 1.73 m² (stage 4), and <15 ml/min per 1.73 m² (stage 5) (5). The guidelines state that the stage of kidney disease should be determined for each CKD patient and that a clinical action plan should be developed on the basis of the stage of disease (5). Thus, inaccurate estimation of kidney function may be responsible for misclassification of some patients and lead to inappropriate evaluation or treatment of these patients (12). However, so far, few studies have assessed the applicability of the MDRD

Received July 13, 2004. Accepted November 24, 2004.

Published online ahead of print. Publication date available at www.jasn.org.

Address correspondence to: Dr. Marc Froissart, Department of Physiology and Biophysics, Georges Pompidou European Hospital, 20 rue Leblanc, 75015 Paris, France. Phone: +33-1-5609-3973; Fax: +33-1-5609-2675; E-mail: marc.froissart@egp.aphp.fr




Figure 1. Relationship between theoretical and measured plasma creatinine concentrations. Increasing amounts of desiccated creatinine hydrochloride were added to plasma samples that were drawn from normal subjects; creatinine concentrations were measured. The measured values then were plotted against the expected values. Solid line represents the linear regression relationship; dashed lines represent the upper and lower boundaries of the 95% confidence interval of the slope of the relationship.

and CG formulas to large cohorts of subjects with wide ranges of renal function. One study compared various formulas with ^{125}I -iothalamate GFR in a cohort of 1703 blacks with presumed hypertensive nephrosclerosis and mean serum creatinine levels of 1.85 ± 0.88 mg/dl (13). All other studies focused on much smaller cohorts of subjects with or without CKD (14–18). Furthermore, with one exception (15), no particular attention was paid to calibration of serum creatinine measurements, although this has been shown to be of critical importance for individuals with normal or near normal serum creatinine values (19,20).

In this study, we compare renal clearance of ^{51}Cr -EDTA (measured GFR) with GFR estimated by the CG formula (CG GFR) or

the MDRD equation (MDRD GFR) in a cohort of 2095 European subjects. Our findings support the preferential use of the MDRD formula but raise caution regarding its usage in some subgroups of individuals, such as young adults with normal renal function or stage 2 CKD or underweight individuals.

Materials and Methods

Patient Selection

Records of all patients who were referred to our Department of Physiology between January 1990 and April 2004 to perform GFR measurements were reviewed retrospectively. For patients who had more than one GFR measurement, only the first one was considered. Renal transplant patients and patients who were younger than 18 yr were excluded. Among the remaining 2178 independent patients, only 83 were black. Because ethnicity is one of the determinants of the MDRD equation, we decided to exclude black patients and restrict the analysis to the 2095 nonblack individuals to ensure statistical relevance of the study. Among them, 1933 had CKD and 162 were healthy potential kidney donors.

GFR Measurements

Renal clearance of ^{51}Cr -EDTA was determined as described previously (21–23). Briefly, 3.5 MBq of ^{51}Cr -EDTA (Amersham Health SA, Pantin, France) was injected intravenously as a single bolus. The injected dose was reduced to 1.8 MBq in patients with an estimated GFR derived from the CG formula of <30 ml/min and in case of body weight <40 kg. After allowing 1 h for distribution of the tracer in the extracellular fluid, urine was collected and discarded. Then, average renal ^{51}Cr -EDTA clearance was determined on five consecutive 30-min clearance periods. Blood was drawn at the midpoint of each clearance period and up to 300 min after injection. The radioactivity measurements in 1-ml plasma and urine samples were carried out on a Packard Cobra 3-inch crystal γ -ray well counter (Boston, MA). When timed urine samples could not be obtained, plasma clearance of ^{51}Cr -EDTA was calculated according to a simplified method described by Brochner-Mortensen (24). This was performed in 219 (10.5%) patients. In our hands, the coefficients of variation of renal clearance of ^{51}Cr -EDTA and plasma clearance of ^{51}Cr -EDTA were 8.4 ± 5.0 and $9.0 \pm 5.3\%$, respectively, whereas the coefficient of variation of inulin clearance was $9.1 \pm 6.3\%$ in the same 22 patients. When compared with inulin renal clearance, the mean bias of EDTA renal clearance was 4.0 ± 4.9 ml/min per 1.73 m 2 (Froissart *et al.*, manuscript in preparation).

Creatinine Assay

All creatinine measurements were performed in the same laboratory. Blood samples were obtained simultaneously with the GFR measure-

Table 1. Demographic and clinical characteristics of study population^a

	Overall (n = 2095)	Female (n = 863)		Male (n = 1232)	
		Age <65 (n = 630)	Age \geq 65 (n = 233)	Age <65 (n = 870)	Age \geq 65 (n = 362)
Plasma creatinine (mg/dl)	1.69 ± 1.25 (1.24/0.91–2.01)	1.29 ± 1.06 (0.91/0.75–1.39)	1.58 ± 1.12 (1.22/0.89–1.94)	1.79 ± 1.31 (1.31/0.97–2.10)	2.22 ± 1.27 (1.77/1.31–2.75)
GFR (ml/min per 1.73 m 2)	61.1 ± 32.7 (59.8/33.6–87.3)	72.2 ± 34.1 (79.0/41.2–97.6)	48.3 ± 26.0 (45.8/27.3–64.2)	64.0 ± 32.5 (65.7/35.5–90.0)	43.3 ± 22.9 (41.9/23.0–60.4)
Age (y)	52.8 ± 16.5 (53.2/40.2–66.7)	43.5 ± 12.2 (44.8/34.8–53.2)	72.9 ± 5.1 (73.0/68.7–76.1)	46.0 ± 12.3 (47.9/36.6–56.0)	72.5 ± 4.8 (72.2/68.3–75.4)
Weight (kg)	70.7 ± 15.3 (69.4/60.0–80.0)	62.7 ± 15.0 (60.0/53.0–69.2)	64.5 ± 11.1 (64.0/56.0–72.0)	76.1 ± 14.1 (75.2/67.0–84.3)	75.8 ± 13.2 (74.4/67.0–82.6)
Height (cm)	167 ± 9 (168/161–174)	161 ± 7 (161/157–166)	157 ± 6 (156/152–160)	173 ± 7 (173/169–178)	170 ± 7 (170/165–174)
BSA (m 2)	1.79 ± 0.21 (1.79/1.64–1.93)	1.65 ± 0.18 (1.63/1.54–1.75)	1.64 ± 0.14 (1.64/1.54–1.74)	1.90 ± 0.18 (1.89/1.78–2.01)	1.87 ± 0.17 (1.85/1.76–1.97)
BMI (kg/m 2)	25.2 ± 4.8 (24.7/22.0–27.8)	24.1 ± 5.8 (22.8/20.6–26.7)	26.3 ± 4.4 (26.2/23.0–29.3)	25.3 ± 4.2 (25.0/22.5–27.7)	26.2 ± 4.4 (25.8/23.8–28.2)

^aData are given as mean \pm SD (median/interquartile range). BSA, body surface area; BMI, body mass index.




Figure 2. (A) Relationship between measured GFR and Modification of Diet in Renal Disease (MDRD) GFR. (B) Bland and Altman plot comparing measured GFR and MDRD GFR. The mean difference (M) is represented by the dashed line.

ment. A modified kinetic Jaffé colorimetric method was used with a Bayer RA-XT and a Konelab 20 analyzer. A five-point calibration was applied in each assay. Before measurement, ultrafiltration of plasma through a 20-kD cutoff membrane (MPS-1; Amicon, Beverly, MA) was performed to discard chromogens that were linked to albumin and other heavy proteins. In the absence of an international standard for

creatinine assay, the linearity of the measurements was verified by using plasma samples from normal subjects in which increasing amounts of desiccated creatinine hydrochloride (MW 149.6; Sigma Chemicals, Perth, Australia) had been added.

Linear regression analysis showed that the slope of the relationship between measured and expected creatinine concentrations was $1.008 \pm$




Figure 3. (A) Relationship between measured GFR and Cockcroft-Gault (CG) GFR. (B) Bland and Altman plot comparing measured GFR and CG GFR. The mean difference (M) is represented by the dashed line.

Table 2. Bias and precision of the MDRD and CG formulas^a

Measured GFR (ml/min per 1.73 m ²)	N	MDRD Formula (ml/min per 1.73 m ²)		CG Formula (ml/min per 1.73 m ²)	
		Bias	Precision	Bias	Precision
≥90	482	−6.2 (−5.3)	18.8 (17.3)	−0.3 (0.2)	22.7 (21.2)
60–89	576	−0.8 (−1.1)	15.1 (20.4)	0.9 (0.9)	15.9 (21.4)
30–59	597	0.6 (1.6)	9.5 (22.6)	2.6 (6.7)	10.9 (25.8)
15–29	312	2.3 (11.3)	7.2 (35.0)	4.9 (24.0)	8.0 (38.7)
<15	128	2.4 (26.8)	5.1 (54.7)	5.2 (54.2)	5.3 (58.7)

^aResults obtained with these formulas were compared with GFR values obtained by measuring the renal clearance of ⁵¹Cr EDTA. The study population was divided into five categories according to the GFR levels used to define the five stages of CKD in the K/DOQI CKD classification (5). Bias is defined as the mean difference between estimated and measured GFR. Precision is 1 SD of bias. MDRD, Modification of Diet in Renal Disease; CG, Cockcroft-Gault; CKD, chronic kidney disease; K/DOQI, Kidney Disease Outcomes Quality Initiative

0.006 (95% confidence interval, 0.997 to 1.020) and that the Y-intercept was 0.014 ± 0.013 (95% confidence interval, −0.013 to 0.041; Figure 1). Squared Spearman rank coefficient of correlation was 0.998. Internal quality controls showed a coefficient of variation of 2.3% during the period. An indirect evaluation of the stability of the measurement was obtained from the ratiometric expression of MDRD/GFR values over time. No clear shift was observed during the entire study period, supporting the absence of variation in creatinine calibration (data not shown). Calibration of our creatinine measurements [HEGPcr.] to the ones of the MDRD laboratory [MDRDcr.] Dr F. Van Lente showed a linear relationship defined by the following equation:

$$[MDRDcr.] = 1.151 \times [HEGPcr.] - 0.107$$

Thus, for serum creatinine ranging from 0.6 to 1.2 mg/dl, the difference between both measurements (MDRDcr. − HEGPcr.) is confined between −0.016 and 0.074 mg/dl.

Creatinine-Based Estimation of GFR

The two formulas that we studied to predict GFR from serum creatinine were the one proposed by Cockcroft and Gault (8):

$$CGGFR = \{ [140 - \text{age}(\text{yr})] \times \text{weight}(\text{kg}) / [7.2 \times \text{PCr}(\text{mg/dl})] \}$$

$$\times (0.85 \text{ if female})$$

and the simplified form of the MDRD formula (10):

$$MDRDGFR = 186.3$$

$$\times \text{PCr}(\text{mg/dl})^{-1.154} \times \text{age}(\text{yr})^{-0.203} \times (1.212 \text{ if black}) \times (0.742 \text{ if female}),$$

where PCr is plasma creatinine concentration.

A correction for body surface area (BSA) was necessary for the CG formula. This was performed using estimated BSA according to Du Bois (25):

$$BSA = \text{weight}(\text{kg})^{0.425} \times \text{height}(\text{m})^{0.725} \times 0.20247$$

Statistical Analyses

Demographic data were expressed as mean \pm SD or median and interquartile range, as appropriate. Estimated and measured GFR are statistically dependent variables. To compare the creatinine-based estimations of GFR with the renal clearance of ⁵¹Cr-EDTA, we used Bland

Table 3. Bias, precision, and accuracy of the MDRD and CG formulas^a

	N	Bland and Altman (ml/min per 1.73 m ²)		Accuracy within (% of Subjects)			CRMSE (ml/min per 1.73 m ²)
		Bias	Precision	15%	30%	50%	
MDRD formula							
high GFR ^b	1044	−3.3	17.2	61.3	92.4	98.8	17.5
low GFR ^c	1051	1.3	8.5	54.8	82.9	93.3	8.6
overall	2095	−1.0	13.7	58.0	87.2	96.0	13.8
CG formula							
high GFR ^b	1044	0.4	19.4	56.1	88.0	97.4	19.4
low GFR ^c	1051	3.5	9.7	41.2	69.0	85.2	10.3
overall	2095	1.9	15.4	48.7	78.5	91.3	15.5

^aResults obtained with these formulas were compared with GFR values obtained by measuring the renal clearance of ⁵¹Cr EDTA. Bias is defined as the mean difference between estimated and measured GFR. Precision is 1 SD of bias. Accuracy was assessed by determining the percentage of subjects who did not deviate >15, 30, and 50% from measured GFR and by calculating the combined root mean square error (CRMSE).

^bMeasured GFR ≥ 60 ml/min per 1.73 m².

^cMeasured GFR <60 ml/min per 1.73 m².

Table 4. Performances of the MDRD and CG formulas according to CKD classes in CKD patients^a

Measured GFR (ml/min per 1.73 m ²)	N	MDRD Formula (ml/min per 1.73 m ²)				CG Formula (ml/min per 1.73 m ²)			
		Bias	Precision	Sensitivity	Specificity	Bias	Precision	Sensitivity	Specificity
≥90	370	−6.3	19.8	65.7	94.9	−1.4	24.0	69.2	93.5
60–89	526	−1.0	15.5	62.7	86.1	0.2	15.9	59.7	85.9
30–59	597	0.6	9.5	78.1	86.8	2.6	10.9	77.9	84.5
15–29	312	2.3	7.2	78.9	93.9	4.9	8.0	67.6	92.8
<15	128	2.4	5.1	64.8	99.3	5.2	5.3	43.0	99.5

^aCKD patients were divided into five categories, according to the GFR levels used to define the five stages of CKD in the K/DOQI CKD classification (5). Results obtained with these formulas were compared with GFR values obtained by measuring the renal clearance of ⁵¹Cr EDTA. Sensitivity and specificity of each formula for assigning patients to the K/DOQI categories of CKD as defined by GFR were also analyzed. Bias is defined as the mean difference between estimated and measured GFR. Precision is 1 SD of bias. Sensitivity is the percentage of well-classified patients within each CKD class. Specificity is the percentage of patients who do not belong to the CKD class of interest and are not classified in this category by the formula.

and Altman recommendations for such evaluations (26). The mean difference between estimated and measured GFR values directly estimates the global bias. The width of the SD of the mean difference is an estimation of precision; a large width means a low precision.

The absolute of the difference between estimated and measured GFR was used to estimate the accuracy of the creatinine-based formulas. It was expressed either in ml/min per 1.73 m² or in percentage of GFR values and was represented in percentiles (50th, 75th, and 90th), allowing to draw absolute and relative boundaries for the lack of accuracy. The accuracy was also measured as the percentage of results that did not deviate >15, 30, and 50% from the measured GFR.

The combined root mean square error (CRMSE) was examined. CRMSE is calculated as the square root of [(mean difference between estimated and measured GFR)² + (SD of the difference)²]. It measures both bias and precision (27). Statistical analyses were performed using Statview 5.0 software (SAS, Cary, NC).

Results

Demographics and GFR Distribution

The main characteristics of the study population are shown in Table 1. All 162 kidney donors were younger than 65 yr. Measured GFR values were equally distributed above (1044 subjects) and below (1051 subjects) 60 ml/min per 1.73 m². For subsequent analyses, the study population was divided into subgroups according to gender, age (18 to 64 yr versus 65 yr or older), and/or measured GFR (≥60 versus <60 ml/min per 1.73 m²).

Two-way ANOVA test showed that measured GFR values differed with respect to gender and age. Women had higher measured GFR values than men (65.8 ± 33.8 versus 57.9 ± 31.5 ml/min per 1.73 m²; *P* < 0.0001). Subjects who were ≥65 yr had lower GFR values than younger ones (45.2 ± 24.3 versus 67.4 ± 33.4 ml/min per 1.73 m²; *P* < 0.0001). However, no significant interaction between gender and age was observed (*P* = 0.2880).

Relationships between Creatinine-Based Estimations of GFR and Measured GFR

The relationships between measured GFR and MDRD GFR or CG GFR are depicted in Figures 2 and 3, respectively. As shown in Figures 2A and 3A, standard regression analyses of these relationships showed a good global agreement between the two variables (*r* = 0.910 and 0.894, respectively). However, as extensively studied by Bland and Altman, the measurement of agreement between two methods should be preferentially expressed using bias plots of the difference against the average (26,28,29). Such a plot showed a mean difference of −0.99 ml/min per 1.73 m² between MDRD GFR and measured GFR (Figure 2B), which corresponds to a statistically significant (*P* = 0.001) but limited bias of the MDRD equation. Similarly, when applied to CG GFR, the Bland and Altman plot showed a mean difference of 1.94 ml/min per 1.73 m² (Figure 3B), which is highly statistically

Table 5. Performances of the MDRD and CG formulas according to CKD classes in kidney donors^a

Measured GFR (ml/min per 1.73 m ²)	N	MDRD Formula (ml/min per 1.73 m ²)		CG Formula (ml/min per 1.73 m ²)	
		Bias	Precision	Bias	Precision
≥90	112	−5.8	15.3	3.3	17.3
60–89	50	0.6	11.5	8.3	14.3

^aKidney donors were divided into two categories, according to the GFR levels used to define the stages of CKD in the K/DOQI CKD classification (5). Results obtained with these formulas were compared with GFR values obtained by measuring the renal clearance of ⁵¹Cr EDTA. Bias is defined as the mean difference between estimated and measured GFR. Precision is 1 SD of bias.




Figure 4. Representation of the mean difference between estimated and measured GFR in the study population. Mean differences are shown according to the formula used to estimate GFR and to age groups and gender.

significant ($P < 0.0001$) but has limited clinical implications. However, for both formulas, the biases were not uniform over the whole range of GFR values (Table 2).

The performance of an equation largely depends on its pre-

cision. The SD of the mean difference was used to characterize the precision of each equation. It was 13.7 and 15.4 ml/min per 1.73 m² for the MDRD and CG formulas, respectively. However, as observed in Figures 2B and 3B, this lack of precision

Table 6. Performance of the MDRD and CG formulas according to gender, age, and GFR levels^a

	MDRD GFR		CG GFR	
	Male	Female	Male	Female
High GFR ^b				
age ≥65 y	-5.9/-8.0 12.1/16.2 (13.5)	-1.6/-1.0 11.5/14.2 (11.6)	-14.5/-19.7 10.4/13.4 (17.9)	-10.7/-12.4 12.2/13.5 (16.2)
age <65 y	-0.6/-0.2 16.4/18.6 (16.4)	-6.1/-5.4 19.3/20.7 (20.3)	3.2/4.1 17.1/19.2 (17.4)	2.5/3.7 22.2/22.7 (22.3)
Low GFR ^c				
age ≥65 y	0.5/5.6 6.7/31.4 (6.7)	1.2/7.6 8.2/34.1 (8.3)	-2.3/-0.2 7.2/32.0 (7.6)	-0.1/7.6 8.0/36.2 (8.0)
age <65 y	1.4/7.0 8.2/27.5 (8.3)	2.3/10.5 10.7/41.6 (10.9)	5.9/24.8 8.8/35.2 (10.6)	8.7/32.8 10.5/43.6 (13.6)
Overall	-0.2/2.7 12.2/25.1 (12.2)	-2.2/1.5 15.6/30.6 (15.7)	1.5/8.0 13.7/30.7 (13.7)	2.5/10.7 17.6/34.5 (17.7)

^aData are presented as bias (absolute/relative), precision (absolute/relative), and (CRMSE), all in ml/min per 1.73 m² or in %.

^bGFR ≥60 ml/min per 1.73 m².

^cGFR <60 ml/min per 1.73 m².




Figure 5. Comparison of accuracy of the MDRD (solid lines) and CG (dashed lines) formulas in GFR prediction, according to gender, age, and measured GFR levels (high GFR, ≥ 60 ml/min per 1.73 m²; low GFR, < 60 ml/min per 1.73 m²). (A) Plotted values are absolute of difference between estimated and measured GFR (expressed in ml/min per 1.73 m²). (B) Plotted values are absolute of relative error between estimated and measured GFR (expressed in %).

was not identical throughout the whole range of GFR values, and both formulas were much more precise for low GFR values. This led us to analyze the precision of each formula according to GFR levels (Table 2). For all categories of GFR, the MDRD formula was more precise than the CG one (Table 2).

Accuracy is a global indicator of the performance of a formula that takes into account its bias and its precision. We tested the accuracy of both formulas in subjects with measured GFR \geq and < 60 ml/min per 1.73 m² by calculating CRMSE and by determining the percentage of subjects who did not deviate > 15 , 30 , and 50% from measured GFR (accuracy within in Table 3). In all cases and with both measurements of accuracy, the MDRD formula had better performances than the CG one (Table 3).

Because the performance of a regression-based equation depends on the population to which the equation is applied, we tested the performance of the equations in CKD patients

and in kidney donors (Tables 4 and 5). We also assessed the sensitivity and the specificity of the two formulas for assigning CKD patients to the categories defined by the K/DOQI CKD classification (Table 4) (5). Performance of the MDRD equation was slightly but not significantly better in kidney donors (Table 5) than in stage 1 or 2 CKD patients (ANOVA, $P = 0.49$, NS). The CG formula was less biased in stage 1 or 2 CKD patients than in kidney donors (ANOVA, $P = 0.001$).

Comparison of Bias and Precision of Estimated GFR Values According to Gender and Age

Besides plasma creatinine values, gender, age, and weight are the three parameters that are taken into account in the MDRD and/or CG formulas. We thus analyzed the performance of these two formulas according to age, gender, and body mass index (BMI). As a first step, we focused on gender and age, because these parameters are used in both formulas.




Figure 6. Representation of the mean difference between estimated and measured GFR in the study population. Mean differences are shown according to the formula used to estimate GFR and to body mass index (BMI). The bars in the upper part of the figure represent the bias value in the whole population. Precision is equal to the SD of the mean difference.

Biases of the MDRD and CG formulas with respect to gender and in two different age groups are shown in Figure 4. A cutoff age of 65 yr was chosen, because data from the United States Renal Data System show that the incident rates of ESRD are more than twofold higher in individuals who are ≥ 65 yr than in younger ones (1). The bias of the MDRD formula was very small in all subgroups, except for women who were younger than 65 yr (bias, -3.1 ± 17.2 ml/min per 1.73 m²), whereas the biases of the CG formula were always significantly larger ($P < 0.0001$).

The precision and the accuracy of the two formulas according to gender and age are reported in Table 6. The MDRD formula was more precise and accurate than the CG one in all subgroups of patients; the only exception was the subgroup of

women who were ≥ 65 yr and had a measured GFR < 60 ml/min per 1.73 m².

Another approach to estimate the global accuracy of the formulas was to analyze the absolute of the difference between estimated and measured GFR values (9,30). It was expressed both in ml/min per 1.73 m² and as a percentage of GFR values and represented in percentiles (50th, 75th, and 90th) to allow the drawing of absolute and relative boundaries for the lack of accuracy (Figure 5). In all cases, the MDRD formula was at least as accurate as the CG one. The CG formula principally lacked accuracy in subjects who were younger than 65 yr and had GFR values < 60 ml/min per 1.73 m², whereas the accuracy of the MDRD formula was much more uniform (Figure 5B).

Table 7. Classification of the study population according to the MDRD and CG formulas^a

Subjects with Measured GFR (ml/min per 1.73 m ²)	N	Classification Based on the MDRD Formula					Classification Based on the CG Formula				
		Stage 1	Stage 2	Stage 3	Stage 4	Stage 5	Stage 1	Stage 2	Stage 3	Stage 4	Stage 5
≥ 90 (stage 1)	482	66.8%	32.6%	0.6%	0%	0%	72.2%	27.6%	0.2%	0%	0%
60–89 (stage 2)	576	15.6%	63.7%	20.5%	0.2%	0%	21.7%	58.7%	19.4%	0.2%	0%
30–59 (stage 3)	597	0.5%	11.9%	78.1%	9.5%	0%	0.5%	13.9%	77.9%	7.7%	0%
15–29 (stage 4)	312	0%	0.3%	16.7%	78.8%	4.2%	0%	0.6%	28.8%	67.6%	2.9%
< 15 (stage 5)	128	0%	0%	3.1%	32.0%	64.8%	0%	0%	3.1%	53.9%	43.0%

^aMeasured GFR was used to divide the study population into five categories corresponding the five stages of CKD in the K/DOQI CKD classification (5). For each category, the subjects then were reclassified according to the MDRD formula and to the CG formula. Numbers in bold correspond to the percentages of subjects who did not change stage when their GFR level was estimated using a creatinine-based formula. The existence of kidney damage was not taken into account for this analysis.

Table 8. Classification of the study population according to the average of MDRD and CG formulas^a

Subjects with Measured GFR (ml/min per 1.73 m ²)	N	Classification Based on the Average of CG and MDRD Formulas				
		Stage 1	Stage 2	Stage 3	Stage 4	Stage 5
≥90 (stage 1)	482	69.5%	30.5%	0%	0%	0%
60–89 (stage 2)	576	17.9%	63.5%	18.4%	0.2%	0%
30–59 (stage 3)	597	0.3%	12.1%	80.1%	7.5%	0%
15–29 (stage 4)	312	0%	0.3%	22.1%	74.4%	3.2%
<15 (stage 5)	128	0%	0%	3.9%	40.6%	55.5%

^aMeasured GFR was used to divide the study population into five categories corresponding the five stages of CKD in the K/DOQI CKD classification (5). For each category, the subjects then were reclassified according to the average of MDRD and CG formulas. Numbers in bold correspond to the percentages of subjects who did not change stage when their GFR level was estimated using a creatinine-based formula. The existence of kidney damage was not taken into account for this analysis.

Comparison of Bias and Precision of Estimated GFR Values According to BMI

The cohort was divided into four standard subgroups according to BMI values: <18.5 kg/m² (underweight, 94 subjects), between 18.5 and 24.9 kg/m² (normal, 1010 subjects), between 25 and 29.9 kg/m² (overweight, 712 subjects), and ≥30 kg/m² (obese, 279 subjects). ANOVA analysis showed that each BMI class was associated with statistically different GFR values (55.1 ± 32.0, 64.3 ± 32.9, 60.9 ± 32.2, and 52.2 ± 31.5 ml/min per 1.73 m² from underweight to overweight subjects, respectively; P < 0.0001). As shown in Figure 6, the MDRD formula largely overestimated kidney function in underweight subjects; the bias observed for this subgroup (12.2 ± 24.8 ml/min per 1.73 m²) was significantly higher than the one observed for all other

classes of BMI (P < 0.0001 by ANOVA test). In all other subgroups, the MDRD formula was less biased, more precise, and more accurate than the CG one (Figure 6).

Consequences of the Limitations of the MDRD and CG Formulas on the K/DOQI CKD Classification

The K/DOQI guidelines recommend defining a clinical action plan for each patient with CKD on the basis of the stage of disease as defined by the K/DOQI CKD classification (5). Therefore, we evaluated the consequences of the limitations of the MDRD and CG formulas on the classification of CKD patients (Table 7). This analysis was based solely on results of GFR determinations, and all 2095 subjects were considered, regardless of whether they had kidney damage. For subjects with GFR ≥90 ml/min per 1.73 m², the CG formula was slightly more accurate than the MDRD one, but for all other GFR levels, more subjects were classified in the proper stage by the MDRD formula than by the CG one (Table 8). Overall, only 70.8 and 67.6% of subjects were classified in the correct stage by the MDRD and CG formulas, respectively. Using the average values of both formulas to estimate GFR did not improve the accuracy of the prediction (Table 8). The consequences of the limitations of the formulas can also be depicted by a figure plotting prediction intervals of measured GFR as a function of estimated GFR (Figure 7).




Figure 7. Predicted values of the measured GFR as a function of the estimated GFR value using the MDRD formula. Solid lines represent the upper and lower boundaries of the 95% confidence intervals of the measured GFR values for each value of estimated GFR. Dotted line represents the mean measured GFR value for each value of estimated GFR.

Discussion

In this study, we evaluated the performances of the CG and MDRD formulas for estimating GFR in a cohort of 2095 subjects. As recommended by the K/DOQI guidelines, these two formulas are increasingly used in daily clinical practice, and decisions regarding the care of CKD patients are based on estimated GFR, but their accuracy is still debated (5).

An important characteristics of our cohort is that it included subjects whose measured GFR ranged from 2.3 to 166.4 ml/min per 1.73 m² (interquartile range, 33.6 to 87.3 ml/min per 1.73 m²), with similar numbers of subjects having measured GFR values ≥ and <60 ml/min per 1.73 m² (1044 and 1051 subjects, respectively). Thus, the performances of the CG and MDRD formulas could be assessed over a wide range of kidney function. Furthermore, because the vast majority of patients included in this study were European, the performances of the

MDRD and CG formulas could be assessed in a group of subjects whose anthropometric characteristics are slightly different from those of Americans. For example, when compared with the MDRD cohort (9,11), the mean weight of our study population was 11.2% lower (70.7 ± 15.3 versus 79.6 ± 16.8 kg) and the mean BSA was 6.3% lower (1.79 ± 0.21 versus 1.91 ± 0.23 kg/m²), whereas, on average, our patients were only 2.2 yr older than those included in the MDRD cohort (52.8 ± 16.5 versus 50.6 ± 12.7 yr) and a similar percentage of subjects were male in both cohorts (59 versus 60%).

Recent studies have emphasized the importance of careful calibration of serum creatinine measurements to estimate reliably GFR in patients with normal or near-normal renal function, using creatinine-based equations (19,20). In the absence of an international standard, we used plasma samples supplemented with precise amounts of creatinine hydrochloride to calibrate our assay. Analysis of the relationship between expected and measured creatinine concentration strongly suggests that our assay reliably measures creatinine concentrations. The relationship between measured and expected creatinine concentrations was linear over a wide range of values and not different from the identity line. Furthermore, in our population, the ratio of MDRD GFR over measured GFR did not vary over time, which suggests that no calibration bias occurred over time. This careful calibration of plasma creatinine measurements may explain that, for subjects with normal or near-normal kidney function, we found much less difference between estimated and measured GFR than in other studies (14,16,18,31).

In this study, GFR was measured by renal clearance of ⁵¹Cr-EDTA, whereas renal clearance of ¹²⁵I-iothalamate has been used by studies in North America. However, the performance of our method is similar to what has been reported for iothalamate clearance (32).

Analysis of bias, a measure of systematic error, in the entire study population showed a very good global agreement between estimated and measured GFR for each of the two formulas. On average, estimated GFR was only 1.0 ml/min per 1.73 m² lower than measured GFR with the MDRD formula and 1.9 ml/min per 1.73 m² higher with the CG formula. A similar bias was observed when the CG formula was compared with GFR measured by ¹²⁵I-iothalamate clearance in all patients who were screened for the African-American Study of Kidney Disease and Hypertension; the mean difference between estimated and measured GFR was -2.7 ml/min per 1.73 m² (13). In contrast, in the MDRD cohort, the CG formula was shown largely to overestimate measured GFR (9). The reasons for this discrepancy are not clear, but it may be due to differences in patient characteristics.

When estimating the performance of a formula, precision is probably more important than bias. Our study showed that both the MDRD and the CG formulas largely lack precision. Previous studies that focused on patients with or without CKD have already highlighted the global lack of precision of these two formulas (13–16,31). However, in our analysis, their performances were different in various subgroups of subjects. The greatest lack of precision was observed for subjects who were younger than 65 yr and had measured GFR ≥ 60 ml/min per 1.73 m² for underweight subjects and, in the case of the CG formula, for obese subjects.

Analysis of the ability of a formula to classify patients into different subgroups depends on the characteristics of the population. In particular, it depends on the proportion of patients who happen to be near the boundaries of the subgroups. In our series, analysis of the performance of both formulas to classify patients according to the K/DOQI CKD classification showed that only 70.8% of subjects were classified in the proper category when using the MDRD formula and 67.6% when using the CG one, which clearly highlights the limitations of both formulas. For example, when using the CG and the MDRD formulas, 28.8 and 16.7% of stage 4 CKD patients were misclassified as stage 3 CKD patients, respectively, which could introduce undue delays in the preparation for renal replacement therapy. By contrast, approximately 20% of subjects with measured GFR ≥ 60 ml/min per 1.73 m² were classified as having stage 3 CKD with both formulas, which could lead to unnecessary assessment of CKD-related complications. Use of the average of the two formulas did not decrease the misclassification rate, which answers to one of the K/DOQI research recommendations (5). So as not to be misled by the use of the formulas when taking care of individual CKD patients, it is probably important to keep in mind the width of the prediction interval for GFR associated with each value of estimated GFR (Figure 7).

In conclusion, in a study population of 2095 European subjects, the MDRD formula provided more reliable estimations of kidney function than the CG formula. However, both formulas lacked precision, and using either one of them for defining the stage of disease according to the K/DOQI CKD classification would have led to inappropriate staging of approximately 30% of subjects.

Acknowledgments

Part of this work was presented during the 35th annual meeting of the American Society of Nephrology in Philadelphia, November 2002.

We gratefully thank Dr. Van Lente for measuring plasma creatinine samples at the Cleveland Clinic Foundation.

References

1. USRDS: Incidence and Prevalence of ESRD. In: *U.S. Renal Data System 2003 Annual Data Report*, Bethesda, MD, National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Diseases, 2003, pp 47–60
2. Schaubel DE, Morrison HI, Desmeules M, Parsons DA, Fenton SS: End-stage renal disease in Canada: Prevalence projections to 2005. *CMAJ* 160: 1557–1563, 1999
3. Stengel B, Billon S, Van Dijk PC, Jager KJ, Dekker FW, Simpson K, Briggs JD: Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990–1999. *Nephrol Dial Transplant* 18: 1824–1833, 2003
4. ERA-EDTA: *ERA-EDTA Registry 2002 Annual Report*, Amsterdam, Academic Medical Center, 2004. Available: www.era-edta-reg.org. Accessed July 12, 2004.
5. National Kidney Foundation: K/DOQI Clinical practice guideline to define chronic kidney disease: Evaluation, classification and stratification. *Am J Kidney Dis* 39[Suppl 1]: S1–S266, 2002
6. Jungers P, Chauveau P, Descamps-Latscha B, Labrunie M, Giraud E, Man NK, Grunfeld JP, Jacobs C: Age and gender-related incidence of chronic renal failure in a French urban

- area: A prospective epidemiologic study. *Nephrol Dial Transplant* 11: 1542–1546, 1996
7. Jager KJ, van Dijk PC, Dekker FW, Stengel B, Simpson K, Briggs JD: The epidemic of aging in renal replacement therapy: An update on elderly patients and their outcomes. *Clin Nephrol* 60: 352–360, 2003
 8. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. *Nephron* 16: 31–41, 1976
 9. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. *Ann Intern Med* 130: 461–470, 1999
 10. Levey AS, Greene T, Kusek JW, Beck GJ: A simplified equation to predict glomerular filtration rate from serum creatinine [Abstract]. *J Am Soc Nephrol* 11: 155A, 2000
 11. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G: The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. *N Engl J Med* 330: 877–884, 1994
 12. Froissart M, Fouqueray B, Houillier P, Jacquot C, Prie D, Rossert J, Urena P, Vrtovsniak F: Classification of the stages of chronic renal disease: Limitations and pitfalls using Cockcroft's formula versus GFR measurement [Abstract]. *J Am Soc Nephrol* 13: 431A, 2002
 13. Lewis J, Agodoa L, Cheek D, Greene T, Middleton J, O'Connor D, Ojo A, Phillips R, Sika M, Wright J Jr: Comparison of cross-sectional renal function measurements in African Americans with hypertensive nephrosclerosis and of primary formulas to estimate glomerular filtration rate. *Am J Kidney Dis* 38: 744–753, 2001
 14. Lin J, Knight EL, Hogan ML, Singh AK: A comparison of prediction equations for estimating glomerular filtration rate in adults without kidney disease. *J Am Soc Nephrol* 14: 2573–2580, 2003
 15. Hallan S, Asberg A, Lindberg M, Johnsen H: Validation of the Modification of Diet in Renal Disease formula for estimating GFR with special emphasis on calibration of the serum creatinine assay. *Am J Kidney Dis* 44: 84–93, 2004
 16. Bostom AG, Kronenberg F, Ritz E: Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels. *J Am Soc Nephrol* 13: 2140–2144, 2002
 17. Stoves J, Lindley EJ, Barnfield MC, Burniston MT, Newstead CG, Vervoort G, Willems HL, Wetzels JF: MDRD equation estimates of glomerular filtration rate in potential living kidney donors and renal transplant recipients with impaired graft function. *Nephrol Dial Transplant* 17: 2036–2037, 2002
 18. Vervoort G, Willems HL, Wetzels JF: Assessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients: Validity of a new (MDRD) prediction equation. *Nephrol Dial Transplant* 17: 1909–1913, 2002
 19. Coresh J, Eknoyan G, Levey AS: Estimating the prevalence of low glomerular filtration rate requires attention to the creatinine assay calibration. *J Am Soc Nephrol* 13: 2811–2812; discussion 2812–2816, 2002
 20. Coresh J, Astor BC, McQuillan G, Kusek J, Greene T, Van Lente F, Levey AS: Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. *Am J Kidney Dis* 39: 920–929, 2002
 21. La Batide-Alanore A, Azizi M, Froissart M, Raynaud A, Plouin PF: Split renal function outcome after renal angioplasty in patients with unilateral renal artery stenosis. *J Am Soc Nephrol* 12: 1235–1241, 2001
 22. Chantler C, Garnett ES, Parsons V, Veall N: Glomerular filtration rate measurement in man by the single injection methods using 51Cr-EDTA. *Clin Sci* 37: 169–180, 1969
 23. Brochner-Mortensen J, Freund LG: Reliability of routine clearance methods for assessment of glomerular filtration rate in advanced renal insufficiency. *Scand J Lab Invest* 41: 91–97, 1981
 24. Brochner-Mortensen J: A simple method for the determination of glomerular filtration rate. *Scand J Lab Invest* 30: 271–274, 1972
 25. Du Bois D, Du Bois EF: A formula to estimate the approximate surface area if height and weight are known. *Arch Intern Med* 17: 863–871, 1916
 26. Bland JM, Altman DG: Statistical methods for assessing agreement between two methods of clinical measurement. *Lancet* 1: 307–310, 1986
 27. Toto RD, Kirk KA, Coresh J, Jones C, Appel L, Wright J, Campese V, Olutade B, Agodoa L: Evaluation of serum creatinine for estimating glomerular filtration rate in African Americans with hypertensive nephrosclerosis: Results from the African-American Study of Kidney Disease and Hypertension (AASK) Pilot Study. *J Am Soc Nephrol* 8: 279–287, 1997
 28. Bland JM, Altman DG: Measuring agreement in method comparison studies. *Stat Methods Med Res* 8: 135–160, 1999
 29. Bland JM, Altman DG: Comparing methods of measurement: Why plotting difference against standard method is misleading. *Lancet* 346: 1085–1087, 1995
 30. Manjunath G, Sarnak MJ, Levey AS: Prediction equations to estimate glomerular filtration rate: An update. *Curr Opin Nephrol Hypertens* 10: 785–792, 2001
 31. Rule AD, Gussak HM, Pond GR, Bergstralh EJ, Stegall MD, Cosio FG, Larson TS: Measured and estimated GFR in healthy potential kidney donors. *Am J Kidney Dis* 43: 112–119, 2004
 32. Perrone RD, Steinman TI, Beck GJ, Skibinski CI, Royal HD, Lawlor M, Hunsicker LG: Utility of radioisotopic filtration markers in chronic renal insufficiency: Simultaneous comparison of 125I-iothalamate, 169Yb-DTPA, 99mTc-DTPA, and inulin. *Am J Kidney Dis* 26: 224–235, 1990